Johnson & Johnson developing stem cell cure for Type 1 diabetes


Johnson & Johnson and biotech company ViaCyte are exploring a possible cure for Type 1 diabetes with encouraging results, The Associated Press reports. The stem cell treatment involves turning embryotic stem cells into insulin-producing cells in a lab, and then putting them in a small capsule to implant under a patient's skin.
Patients with Type 1 diabetes cannot produce insulin. In a healthy person, insulin is made by the body in response to rising blood sugar levels after a meal. High levels of sugar in the bloodstream can lead to the damage of blood vessels, organs, and can even kill patients. Type 1 diabetes patients need to take frequent insulin injections as a result — something the insulin-implant produced by ViaCyte and Johnson & Johnson would render unnecessary.
Testing began on patients a year ago; they received a small dose of the insulin-producing cells in their implants and are to be closely monitored for two years. The companies reported that after 12 weeks, the patient's devices were working as expected with no side effects observed. Another several rounds of patient testing are expected before regulators will approve the device.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
About 29.1 million Americans have diabetes, which includes 1.25 million with Type 1, or insulin-dependent, diabetes. Type 2 diabetics — whose bodies make insulin but use it ineffectively — are on the rise, as are Type 1 diabetics. Current treatment includes a strict diet, exercise, and multiple daily insulin injections and finger-prick blood tests.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Jeva Lange was the executive editor at TheWeek.com. She formerly served as The Week's deputy editor and culture critic. She is also a contributor to Screen Slate, and her writing has appeared in The New York Daily News, The Awl, Vice, and Gothamist, among other publications. Jeva lives in New York City. Follow her on Twitter.
-
Musk's latest Grok AI controversy and what it reveals about chatbots
In the Spotlight The spread of misinformation serves as a reminder of how imperfect chatbots really are
-
Get a taste of a place at these regional US restaurant chains
The Week Recommends Eat where the locals do
-
Bombing of fertility clinic blamed on 'antinatalist'
speed read A car bombing injured four people and damaged a fertility clinic and nearby buildings in Palm Springs, California
-
Pro-EU centrist beats Trump acolyte in Romania vote
speed read The mayor of Bucharest, Nicusor Dan, defeated hard-right nationalist George Simion in the race for Romania's presidency
-
Kurdish PKK militia to disband for Turkey talks
speed read The Kurdistan Workers' Party will disarm after four decades of armed conflict with Turkey, putting an end to 'one of the longest insurgencies in the Middle East'
-
US, China agree to lower tariffs for 90 days
speed read US tariffs will fall to 30% from 145%, while China will cut its tax on US imports to 10% from 125%
-
India strikes Pakistan as tensions mount in Kashmir
speed read Pakistan's Prime Minister Shehbaz Sharif called it an 'act of war'
-
Israel approves plan to take over Gaza indefinitely
speed read Benjamin Netanyahu says the country is 'on the eve of a forceful entry'
-
Putin talks nukes as Kyiv slated for US air defenses
speed read 'I hope they will not be required,' Putin said of nuclear weapons on Russian state TV
-
US, Ukraine sign joint minerals deal
speed read The Trump administration signed a deal with Ukraine giving the US access to its mineral wealth
-
What happens if tensions between India and Pakistan boil over?
TODAY'S BIG QUESTION As the two nuclear-armed neighbors rattle their sabers in the wake of a terrorist attack on the contested Kashmir region, experts worry that the worst might be yet to come